Trial Profile
Phase I study of erlotinib and sunitinib in non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2019
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Sunitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 13 Feb 2012 Actual patient number 11 added as reported by ClinicalTrials.gov.
- 13 Feb 2012 Actual end date Aug 2011 added as reported by ClinicalTrials.gov.
- 13 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.